Before the world even imagined that 4 million drug-eluting stents would be available in 36 countries around the world, the founders of MicroPort® were imagining how they would impact the lives of people through technology. Their belief was that these medical technologies must be accessible to everyone.

Relentless innovation has inspired promising product development and initiated strategic investments in emerging scientific platforms. Today, we see a promising path forward, one that addresses the most challenging healthcare issues, while allowing us to explore the ways to accelerate and broaden access to medical technology innovation.

MILESTONES 2020
The MicroPort Group and its associated companies introduced external financing of over US$1 billion accumulatively and widely recognized by the capital market.

MicroPort® and NDR, a developer of automated needle targeting Robotics systems, announced strategic investment and agreement to establish a joint venture in China

MicroPort® and Robocath, a vascular interventional robot company, reached a strategic investment agreement and signed a binding framework agreement for the establishment of a joint venture in China

MicroPort® and Siemens Healthcare reached a strategic cooperation agreement on medical angiography X-ray machines

MicroPort® strategically invested in an Indian medical device company, Purple Medical, and established a joint-venture company

MicroPort® (00853.HK) was included in the MSCL Hong Kong Index

MicroPort® (00853.HK) was included in the Hang Seng Composite Mid-Cap Index and Large Mid-Cap Index and officially entered the Shanghai-Hong Kong Stock Connect

MicroPort® Orthopedics` first domestic total hip replacement system was approved for marketing

MicroPort® NeuroTech Numen® System was approved for China Domestic Market

MicroPort® announced the results of a 3-year clinical study of Firehawk® TARGET AC stents, first announced at EuroPCR, further confirming the long-term safety and efficacy of the world’s lowest drug-loaded coronary drug stents

Initiated “1+12+5” operating model and began exponential growth

MicroPort Scientific Corporation Videos

Evolution Kinematic Alignment Patient Education Animation- Video

Firehawk Rapamycin Target Eluting Coronary Stent System Features - Video

Contact supplier